Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024.
Minaris Regenerative Medicine (“Minaris”), a leading cell therapy contract development and manufacturing organization, is pleased to announce that its parent company, Resonac Corporation (“Resonac”), has entered into a definitive agreement to sell Minaris to a fund managed by Altaris, LLC (collectively with its managed funds, “Altaris”). Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Subject to customary closing conditions, Resonac has agreed to transfer all issued shares of the three Minaris subsidiaries (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, and Minaris Regenerative Medicine GmbH in Germany) to Altaris.
“The agreement to transfer shares of Minaris to Altaris, a firm with a track record of building companies that deliver value to the healthcare system, should prove to be transformative for Minaris,” said Dr. Hiroto Bando, CEO of Minaris. “We look forward to partnering with Altaris as we continue to grow our business globally.”
During this interim period, Minaris’ daily business operations, and commitment to its clients, remains the same.
Resonac has issued a press release about this transaction located here (https://www.resonac.com/news/2024/09/24/3285.html)
About Minaris Regenerative Medicine
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with 25 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply life-changing therapies to patients globally.
For more information, please visit www.rm.minaris.com
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com
*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.
